- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Truseltiq
Synonyms :
infigratinib
Class :
FGFR Inhibitors
Dosage forms & Strengths:
Capsule
25 mg
100 mg
125
mg
Orally
once a day
21
days
Capsule
Then 7 days off of medication
Each cycle lasts 28 days
Safety and efficacy are not seen in pediatrics
refer adult dosing
infigratinib: they may diminish serum concentrations of antacids
infigratinib: they may diminish serum concentrations of antacids
may diminish the serum concentration of Antacids
they decrease the concentration of active metabolites of infigratinib in the serum
they decrease the concentration of active metabolites of infigratinib in the serum
they decrease the concentration of active metabolites of infigratinib in the serum
they decrease the concentration of active metabolites of infigratinib in the serum
they decrease the concentration of active metabolites of infigratinib in the serum
they decrease the concentration of active metabolites of infigratinib in the serum
they decrease the concentration of active metabolites of infigratinib in the serum
they decrease the concentration of active metabolites of infigratinib in the serum
they decrease the concentration of active metabolites of infigratinib in the serum
they decrease the concentration of active metabolites of infigratinib in the serum
they decrease the concentration of active metabolites of infigratinib in the serum
they decrease the concentration of active metabolites of infigratinib in the serum
they decrease the concentration of active metabolites of infigratinib in the serum
they decrease the concentration of active metabolites of infigratinib in the serum
they decrease the concentration of active metabolites of infigratinib in the serum
CYP3A4 Inhibitors (Moderate) may decrease serum concentrations when combined with the active metabolite(s) when combined with Infigratinib
CYP3A4 Inhibitors (Moderate) may decrease serum concentrations when combined with the active metabolite(s) when combined with Infigratinib
CYP3A4 Inhibitors (Moderate) may decrease serum concentrations when combined with the active metabolite(s) when combined with Infigratinib
CYP3A4 Inhibitors (Moderate) may decrease serum concentrations when combined with the active metabolite(s) when combined with Infigratinib
CYP3A4 Inhibitors (Moderate) may decrease serum concentrations when combined with the active metabolite(s) when combined with Infigratinib
infigratinib: they may diminish serum concentrations of CYP3A4 Inducers
infigratinib: they may diminish serum concentrations of CYP3A4 Inducers
infigratinib: they may diminish serum concentrations of CYP3A Inhibitors
infigratinib: they may diminish serum concentrations of CYP3A Inhibitors
nafcillin will decrease the effect of action of infigratinib by affecting enzyme CYP3A4 metabolism.
the effect of infigratinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
lapatinib increases the effect of infigratinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A strong enhancers of the small intestine may reduce the bioavailability of infigratinib
CYP3A4 inducers decrease the concentration of active metabolites of infigratinib in serum
may diminish the serum concentration of CYP3A4 inhibitors
they decrease the concentration of active metabolites of infigratinib in the serum
they decrease the concentration of active metabolites of infigratinib in the serum
they decrease the concentration of active metabolites of infigratinib in the serum
they decrease the concentration of active metabolites of infigratinib in the serum
they decrease the concentration of active metabolites of infigratinib in the serum
they decrease the concentration of active metabolites of infigratinib in the serum
Actions and Spectrum:
Action:
Inhibition of FGFRs: Infigratinib inhibits the activity of fibroblast growth factor receptors, which are often overactive in cancer cells with specific genetic mutations. By blocking these receptors, the drug disrupts the signaling pathways that promote cancer cell growth and proliferation.
Anti-Angiogenic Effects: Infigratinib’s inhibition of FGFRs can also have anti-angiogenic effects. Angiogenesis is the process of forming new blood vessels to supply nutrients and oxygen to growing tumors. By blocking FGFRs, infigratinib can interfere with the signals that promote angiogenesis, potentially starving the tumor of its blood supply.
Spectrum:
Bladder Cancer: Infigratinib is indicated for the treatment of advanced or metastatic bladder cancer with FGFR3 or FGFR2 genetic alterations.
Cholangiocarcinoma: It’s also used to treat advanced or metastatic cholangiocarcinoma (bile duct cancer) with FGFR2 gene fusions or rearrangements.
Other Solid Tumors: Infigratinib is being investigated for its potential in treating other solid tumors that have FGFR genetic alterations, such as certain types of lung cancer.
Contraindication / Caution:
infigratinib is contraindicated in patients hypersensitive to the active ingredient.
Pregnancy consideration:
No data is available regarding the usage of the drug during pregnancy
Breastfeeding warnings:
No data is available regarding the excretion of the drug in breast milk.
Pregnancy category:
Category N: There is no data available for the drug under this category
Patient information leaflet
Generic Name: infigratinib
Pronounced: in-fig-rat-i-nib.
Why do we use infigratinib?
infigratinib is used as a targeted therapy for the treatment of specific types of advanced or metastatic cancers that have certain genetic alterations involving fibroblast growth factor receptors (FGFRs). These alterations can result in abnormal signaling pathways that contribute to cancer growth and progression. By inhibiting these FGFRs, infigratinib helps to disrupt these signaling pathways and inhibit the growth and spread of cancer cells.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
